There are two FDA-approved endobronchial valves on the market for bronchoscopic lung volume reduction — the Zephyr® valve and the Spiration® valve. Both valves have been proven effective for patients with severe emphysema. Additional devices are currently being tested as part of clinical trials.
The type of valve chosen is decided on by your medical team. If you do not qualify for BLVR, the Temple Lung Center has other options that may help you breathe easier and improve your quality of life.
About the Zephyr Endobronchial Valve
The Zephyr® Endobronchial Valve was FDA approved in 2018 after it was proven effective by the Temple-led LIBERATE clinical trial.* This tiny device functions as a one-way valve, causing the damaged parts of the lung to deflate and preventing further inflation. The device shrinks the diseased regions of the lung and allows healthier regions to expand and function more efficiently.
The Zephyr® valve was designed with placement functionality in mind. The valve sizing allows for a quick visual assessment of the bronchial diameter, while a depth marker notes the position for the catheter placement. An actuator lever then assists in the action of deploying the valve into the lung.
In the LIBERATE trial, almost half of patients who received the Zephyr® valves had improved lung function, compared with 17% of patients treated with current standard medical management approaches. Patients who responded to the Zephyr® valves were able to breathe easier, increase their exercise capacity and enjoy a better quality of life.
While patients who remained on standard drug therapy did not change or worsen over time, the patients who responded to Zephyr® therapy continued to experience medical benefits 12 months after receiving treatment. Over the long-term, the frequency of adverse events between the two study groups was comparable.